Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Hedge Funds Cut Nvidia, Amazon and Microsoft Stakes as AI Valuation Concerns Rise 
Freedom Finance and Binance Join Forces in Digital Assets 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
Waymo Clarifies Role of Remote Workers Amid U.S. Robotaxi Safety Scrutiny 
Yotta to Build $2 Billion AI Data Centre Hub in India with Nvidia Blackwell Ultra Chips 
DUBLIN, IRELAND, May 01, 2018 -- Horizon Pharma plc (NASDAQ:HZNP), today announced that the company will participate in the following conference in May:
UBS Global Healthcare Conference
- Date: May 22, 2018
- Presentation Time: 9:30 a.m. ET
- Location: New York
The presentation will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com. A replay of the webcast will be available for the event.
About Horizon Pharma plc
Horizon Pharma plc is focused on researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases. By fostering a growing pipeline of medicines in development and exploring all potential uses for currently marketed medicines, we strive to make a powerful difference for patients, their caregivers and physicians. For us, it’s personal: by living up to our own potential, we are helping others live up to theirs. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter, like us on Facebook or explore career opportunities on LinkedIn.
| Contacts: | |
| Investors: Tina Ventura Senior Vice President, Investor Relations [email protected] | U.S. Media: Geoff Curtis Senior Vice President, Corporate Affairs & Chief Communications Officer [email protected] |
| Ruth Venning Executive Director, Investor Relations [email protected] | Ireland Media: Ray Gordon Gordon MRM [email protected] |
